Study identifier:NIS-GES-DUM-2007/3
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Symptomatic assessment and therapeutic outcomes in typical GERD patients following a new CP guideline in the clinical practice
GERD
-
No
-
All
300
Observational
17 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2009 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
To evaluate symptomatic outcome and HRQoL in GERD patients treated following a new CP Guideline.
Location
Location
A CORUNA, La Coruna, Spain
Location
ALZIRA, Valencia, Spain
Location
BADAJOZ, Badajoz, Spain
Location
BARACALDO, Vizcaya, Spain
Location
BARCELONA, Barcelona, Spain
Location
BILBAO, Vizcaya, Spain
Location
CABRA, Cordoba, Spain
Location
CADIZ, Cadiz, Spain
Arms | Assigned Interventions |
---|---|
GERD patients Patients with typical GERD symptoms | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.